David M. Polen
Polen Capital Management
Polen Capital Management Praxis Precision MedicinesInc stake
total: 588
Polen Capital Management PRAX trades
- Total transactions:
- 2
- New positions:
- 1
- Reduced:
- 1
- Held since:
- 2026 Q1
- Held for:
- 2 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Polen Capital Management holds 7,252 Praxis Precision MedicinesInc (PRAX) shares with a market value of roughly $2.43M accounting for 0.02% of the overall portfolio. To date, the estimated cost basis is nearly $322.19 for "buy" trades and estimated average "sell" price is $334.79. Polen Capital Management first purchased PRAX in 2026 Q1, initially acquiring 10,043 shares. Since the initial investment in Praxis Precision MedicinesInc (PRAX), Polen Capital Management has made 1 more transaction.
When did Polen Capital Management buy Praxis Precision MedicinesInc (PRAX)?
Polen Capital Management first invested in Praxis Precision MedicinesInc (PRAX) in 2026 Q1 at the reported quarter-end price of $322.19 per share.
What's the cost basis of Polen Capital Management's PRAX stake?
The estimated cost basis for Praxis Precision MedicinesInc (PRAX) stake is around $322.19 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $322.19
- Weighted AVG sell price:
- $334.79
Polen Capital Management's historical trades in Praxis Precision MedicinesInc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.02%
|
7,252
|
$334.79
|
$2,427,897
|
-27.79% (-2,791)
|
-0.01%
|
|
2026 Q1
|
0.02%
|
10,043
|
$322.19
|
$3,235,754
|
new
|
+0.02%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.